Impact of PCSK9 Inhibitors on Lipoprotein(a) Levels: A Multi-Center Study

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Elevated lipoprotein(a) [Lp(a)] is a significant, genetically determined risk factor for atherosclerotic cardiovascular disease.
• Currently, no targeted therapies specifically aim to lower Lp(a).
• Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are effective lipid-lowering agents, but their impact on Lp(a) levels is variable.

Purpose of the Study:

• To evaluate the real-world effectiveness of PCSK9 inhibitors in reducing Lp(a) levels.
• To identify predictors of Lp(a) reduction in patients treated with PCSK9i.

Main Methods:

• A multi-center, retrospective study analyzed data from 453 adults prescribed PCSK9i with available Lp(a) measurements before and after treatment.
• Multivariable linear regression was used to identify predictors of Lp(a) reduction.
• A control group of 6750 individuals with serial Lp(a) measurements was used for comparison.

Main Results:

• PCSK9i therapy was associated with a median Lp(a) reduction of 17.3% (11.3 mg/dL) overall.
• Patients with baseline Lp(a) >50 mg/dL experienced a median reduction of 17.7% (19.2 mg/dL).
• Higher baseline Lp(a) levels and male sex were significant predictors of greater Lp(a) reduction.

Conclusions:

• PCSK9 inhibitors demonstrate modest, real-world Lp(a) lowering of approximately 17%.
• The percent reduction in Lp(a) was consistent across different Lp(a) assay types and PCSK9i types.
• Baseline Lp(a) level and sex are key predictors of treatment response, independent of age, race/ethnicity, or comorbidities.